Ann: Key Opinion Leader Presentation, page-79

But you can be bothered to post day-in, day-out snipes at RCE. A stock you either irrationally or lazily didn't sell out of despite your assertions it going down, that now you are putting in the bottom draw and waiting for it to go up!!! Can you not see the absurd contradiction in logic?

Perhaps discussions of US Dept. Grants and collaborations, balance, sheets, R&D revenues, cash flow statements, even if they serve you and others to sell out of your assets, might be a more prudent approach to investment. Anything but the useless negative drivel that persists on RCE threads....

You know actual discussion for example of the topic of this thread for example.

Shareholders who actually watched the webinar, like me already disappointed on the lack of data detail on the recent phase II trial results, might have been a bit bemused to the detail the principal clinical investigator and the chief medical advisor went to on Lipsky and Benson/Jenson measures per the primary endpoints, without actually revealing them. Now that might be fair criticism on an investor forum discussion.

But similarly, like me, one might think the principle investigator, keen to emphasize the FDA's acceptance of these parameters and his discussion of improved efficacy under those measures, counter-balanced by some optimism there. Similarly, they might like me, have been surprised to hear the CMA describe some of the patients as "cured" several times, within 14 days. They might like me, feel some scepticism on that declaration without seeing actual scores, but similarly be surprised to hear such assertive words used, in after all what is a conservative profession, in a phase II trial on preliminary efficacy and safety.

I mean if RCE 327 gel really is and I quote "curing" patients within 14 days (I remain healthily sceptical until I see firmer evidence) versus more typical healing ranges in the 3 -12 week mark (those that do) under SOC, then perhaps for all its risks faced in getting to commercialisation, $75 million was a bit cheap for this stock.